Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$76,010.00-5.41%ETH$2,233.05-7.48%GOLD$4,096.80-0.41%OIL$91.23+0.78%
Smart Investors Daily
SID Premium
DR

NASDAQ · DRTSW

Alpha Tau Medical Ltd.

Healthcare · Biotechnology

$3.60

Down-$0.46 (-12.78%)

Updated Nov 6, 2026, 1:30 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
31.51M
P/E ratio
-10.28
Dividend yield
0.00%
52-week range
$0.72 – $4.62
Volume
12.37K
Avg. volume
15.87K

Price performance · DRTSW

DRTSW price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

DRTSW closed at $3.60 after 20 trading sessions, up 1.12% for the selected period.

Last close
$3.60
Period change
+1.12%
Period low
$2.68
Period high
$3.92
Daily close
View OHLC price history
DRTSW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$3.50$3.70$3.20$3.6012.37K
Nov 3, 2026$3.00$3.45$2.89$3.3242.82K
Nov 2, 2026$3.00$3.01$2.98$3.002.53K
Oct 30, 2026$3.25$3.25$2.96$2.962.09K
Oct 29, 2026$3.32$3.42$3.16$3.2519.06K
Oct 28, 2026$3.54$3.54$3.385$3.464.87K
Oct 27, 2026$3.10$3.54$3.10$3.544.38K
Oct 26, 2026$2.43$3.19$2.43$3.0013.81K
Oct 23, 2026$3.19$3.30$3.19$3.246.62K
Oct 22, 2026$3.40$3.40$3.11$3.1115.56K
Oct 21, 2026$3.71$3.71$3.40$3.6116.22K
Oct 20, 2026$2.90$3.39$2.8001$3.3054.47K
Oct 19, 2026$2.65$3.02$2.65$2.9533.92K
Oct 16, 2026$2.97$2.97$2.355$2.6843.37K
Oct 15, 2026$3.50$3.50$2.82$2.9944.37K
Oct 14, 2026$3.62$3.64$3.3001$3.6216.45K
Oct 13, 2026$3.74$3.74$3.52$3.57920.78K
Oct 12, 2026$3.60$3.80$3.60$3.7352.72K
Oct 9, 2026$3.75$3.935$3.6301$3.925.55K
Oct 8, 2026$3.62$3.62$3.33$3.5682.18K

Latest DRTSW news

The latest Smart Investors Daily articles mentioning DRTSW.

Stock researchCompany · Overview

DRTSW research

Overview

Company profile and research snapshot.

Company profile

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer Trial

Alpha Tau Medical reported that the FDA approved an IDE supplement for its U.S. REGAIN trial in recurrent glioblastoma, expanding enrollment to 20 patients, widening eligibility to include IDH-mutant grade 4 tumors, and adding new clinical endpoints and interim analysis. The firm is set to present the first REGAIN trial data at the Society for Neuro-Oncology Annual Meeting. This signals growing scientific engagement around Alpha DaRT’s use in hard to treat brain tumors and raises the...

Yahoo · Oct 19, 2026

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua Palmer of The Ohio State University accepted for presentation at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting, marking the trial’s first appearance at a scientific meeting - - Glioblastoma is the most common malignant primary brain tumor in the U.S. - JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE

Yahoo · Oct 5, 2026

Alpha Tau to Participate in October Investor Conferences

JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026. Event:Fall Focus: Barclays Biotech 1x1 DayFormat:1x1 MeetingsDate:Tuesday, October 6, 2026Location:New York, NY Event:Investment Generation ConferenceFormat:PresentationDate:Thursday, Octob

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By